SafetyMargin.ioSafetyMargin.io
BlogWatchlistCompare
Compare Stocks › ABBV vs REGN

AbbVie Inc. (ABBV) vs Regeneron Pharmaceuticals, Inc. (REGN): Which Is the Better Buy in 2026?

As of 2026-09-17, ABBV is overvalued at $264, with a DCF intrinsic value of $184 and a margin of safety of -44%. REGN is undervalued at $789, with an intrinsic value of $1305 and a margin of safety of 40%. Of the two, REGN has the wider margin of safety.

ABBV
AbbVie Inc.
$264.02
VS
REGN
Regeneron Pharmaceuticals, Inc.
$789.45

Rewards

ABBV
  • ★AbbVie Inc. has maintained ROIC above 10% for 4 consecutive years, suggesting solid business economics.
  • ★Gross margin of 72.8% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • ★AbbVie Inc. scores 82/100 on the Economic Moat Score (Wide Moat), with reinvestment efficiency as the strongest competitive dimension.
REGN
  • ★Regeneron Pharmaceuticals, Inc. scores 80/100 on the Economic Moat Score (Wide Moat), with revenue predictability as the strongest competitive dimension.
  • ★Altman Z-Score of 7.56 indicates very low bankruptcy risk — the company is firmly in the safe zone.
  • ★Net debt/EBITDA of -1.1x means the company holds more cash than debt — a net cash position.

Risks

ABBV
  • ⚠Buybacks have been poorly timed — 3 out of 4 years involved repurchases at relatively expensive valuations.
  • ⚠Insiders have sold $8.2M worth of stock in the past 3 months — significant insider liquidation.
  • ⚠Free cash flow has declined at a 9.8% CAGR over the past 4 years — a concerning trend.
REGN
  • ⚠ROIC has declined by 7.3 percentage points over the past 4 years, which may signal competitive erosion.
  • ⚠Each dollar of retained earnings has produced only $0.15 of earning power — shareholders may have been better served by dividends.
  • ⚠5 insider sales totaling $3.4M with no purchases in the past 3 months — insiders are reducing their exposure.

Key Valuation Metrics

Learn more →
ABBV
REGN
Valuation
$16.87B
Free Cash Flow
$3.07B
3.62%
FCF Yield
3.77%
74.58
Trailing P/E
19.53
16.23
Forward P/E
13.02
Quality & Moat
28.73%
ROIC
11.80%
N/A
ROE
14.04%
72.79%
Gross Margin
44.46%
0.54
PEG Ratio
1.27
Balance Sheet Safety
N/A
Net Debt / Equity
Net cash
N/A
Interest Coverage
N/A
2.09
Net Debt / EBITDA
-1.12
2.64%
Dividend Yield
0.49%
ABBV: 5Ties: 2REGN: 3
ABBVREGN

Historical Fundamentals

Learn more →
ABBV

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

REGN

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

$1 Retained Earnings Test

Learn more →
ABBV
N/A
Net losses over 3 years — test not applicable
Company had negative cumulative retained earnings
Σ Retained
$-19.85B
Δ Market Cap
+$118.02B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
REGN
$0.20
created per $1 retained over 3 years
Value Destroyer
Σ Retained
$12.50B
Δ Market Cap
+$2.52B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

Discounted Cash Flow (DCF) Analysis

Learn more →
ABBV
43.5% Overvalued
Price is 43.5% above estimated fair value
Current Price: $264.02
Fair Value: $183.97
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued
REGN
39.5% Margin of Safety
Price is 39.5% below estimated fair value
Current Price: $789.45
Fair Value: $1305.03
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued

Reverse DCF — Market-Implied Growth

Learn more →
ABBV

What growth rate is the market pricing in at $264?

+19.5%
Market-Implied Owner Earnings Growth
Standard FCF implies +13.9%

The market implies +19.5% Owner Earnings growth, above historical trends.

Standard FCF implies a demanding +13.9%, reflecting heavy growth investment.

REGN

What growth rate is the market pricing in at $789?

+5.4%
Market-Implied Owner Earnings Growth
Standard FCF implies +10.6%

The market implies +5.4% Owner Earnings growth, above historical trends.

Standard FCF implies a demanding +10.6%, reflecting heavy growth investment.

Economic Moat Score

Learn more →
ABBV
82/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None

Wide moat with strength across all dimensions. Reinvestment Efficiency is the standout factor.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
REGN
80/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None

Wide moat with strength across all dimensions. Revenue Predictability is the standout factor.

Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.

Forensic Accounting

Learn more →
ABBV
-2.86
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
REGN
-2.51
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

M-Score Trend

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

Ownership Breakdown

Learn more →
ABBV
Insiders 0.1%Institutions 77.4%Retail & Other 22.5%
No. of Institutional Holders5,262
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
REGN
Insiders 2.1%Institutions 93.6%Retail & Other 4.3%
No. of Institutional Holders1,923
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

Insider Buying Activity

Learn more →
ABBV
0
Buys (3M)
0
Buys (12M)
No open market insider purchases found.
Open market purchases · includes direct & indirect ownership · excludes option exercises
REGN
0
Buys (3M)
0
Buys (12M)
No open market insider purchases found.
Open market purchases · includes direct & indirect ownership · excludes option exercises

Open market purchases · includes direct & indirect ownership · excludes option exercises.

Insider Selling Activity

Learn more →
ABBV
1
Sells (3M)
4
Sells (12M)
Total value (12M): $18.92M
DONOGHOE NICHOLAS
Officer
$8.18M
@ $250.00 · 2026-08-14
PURDUE DAVID RYAN
Officer
$1.22M
@ $233.56 · 2026-03-04
SIATIS PERRY C.
General Counsel
$4.38M
@ $234.39 · 2026-03-02
SIATIS PERRY C.
General Counsel
$5.15M
@ $230.00 · 2026-02-25
SALEKI-GERHARDT AZITA
Chief Operating Officer
$8.41M
@ $198.42 · 2025-08-12
DONOGHOE NICHOLAS
Officer
$2.64M
@ $198.51 · 2025-08-05
STEWART JEFFREY RYAN
Officer
$12.36M
@ $210.08 · 2025-03-31
REENTS SCOTT T.
Chief Financial Officer
$3.75M
@ $212.34 · 2025-03-14
RICHMOND TIMOTHY J
Officer
$4.47M
@ $210.45 · 2025-03-03
SIATIS PERRY C.
General Counsel
$5.82M
@ $208.69 · 2025-03-03
GONZALEZ RICHARD A
Director
$20.26M
@ $205.45 · 2025-03-03
RICHMOND TIMOTHY J
Officer
$6.07M
@ $202.90 · 2025-02-26
BUCKBEE KEVIN K
Officer
$3.85M
@ $203.41 · 2025-02-26
SIATIS PERRY C.
General Counsel
$1.14M
@ $197.90 · 2025-02-20
BUCKBEE KEVIN K
Officer
$310,032
@ $172.24 · 2024-12-16
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
REGN
5
Sells (3M)
15
Sells (12M)
Total value (12M): $12.91M
MCCOURT MARION E
Officer
$2.00M
@ $853.56 · 2026-09-03
GUARINI KATHRYN PH.D.
Director
$340,000
@ $850.00 · 2026-09-02
GUARINI KATHRYN PH.D.
Director
$320,000
@ $800.00 · 2026-08-10
ZOGHBI HUDA Y
Director
$640,000
@ $800.00 · 2026-08-10
RYAN ARTHUR F.
Director
$130,030
@ $650.15 · 2026-07-02
RYAN ARTHUR F.
Director
$70,524
@ $705.24 · 2026-05-01
RYAN ARTHUR F.
Director
$77,727
@ $777.27 · 2026-04-01
RYAN ARTHUR F.
Director
$78,550
@ $785.50 · 2026-03-02
ZOGHBI HUDA Y
Director
$1.28M
@ $781.33 · 2026-02-19
RYAN ARTHUR F.
Director
$77,853
@ $778.53 · 2026-02-09
PITOFSKY JASON
Officer
$1.59M
@ $778.52 · 2026-02-09
BASSLER BONNIE L
Director
$1.20M
@ $800.00 · 2026-01-07
BASSLER BONNIE L
Director
$570,000
@ $750.00 · 2025-11-20
PITOFSKY JASON
Officer
$280,766
@ $651.43 · 2025-11-07
POON CHRISTINE A
Director
$4.25M
@ $654.27 · 2025-10-29
MCCOURT MARION E
Officer
$844,610
@ $844.61 · 2024-11-01
RYAN ARTHUR F.
Director
$104,878
@ $1048.78 · 2024-10-01
MCCOURT MARION E
Officer
$1.05M
@ $1054.06 · 2024-10-01
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

🎭 Mr. Market's Mood

Learn more →
ABBV
FearGreed
😏Greed(69/100)

"Market is optimistic — be cautious and ensure you have a margin of safety"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
REGN
FearGreed
😐Neutral(58/100)

"Market is pricing this stock without strong emotion in either direction"

Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

⚖️ Buffett Signal

Learn more →
ABBV
⚪Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Greed (69)
REGN
⚪Awaiting DCF Data

The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

DCF Margin of Safety: N/AMr. Market's Mood: Neutral (58)
View ABBV Full AnalysisView REGN Full Analysis

Frequently Asked Questions: ABBV vs REGN

Is AbbVie Inc. or Regeneron Pharmaceuticals, Inc. more undervalued in 2026?▼

Based on our discounted cash flow model, REGN trades at a 39.5% margin of safety (intrinsic value $1305 vs. price $789), compared to ABBV's -43.5% margin of safety (intrinsic $184 vs. $264).

Which stock has a wider economic moat, AbbVie Inc. or Regeneron Pharmaceuticals, Inc.?▼

ABBV scores 82/100 (Wide moat), while REGN scores 80/100 (Wide moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

Is AbbVie Inc. in financial distress?▼

ABBV's Altman Z-Score of 2.4 places it in the Grey zone, signaling elevated bankruptcy risk. REGN scores 7.6 (Safe zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

Which company has better free cash flow, AbbVie Inc. or Regeneron Pharmaceuticals, Inc.?▼

Regeneron Pharmaceuticals, Inc. (REGN) generates a 3.8% free cash flow yield, compared to AbbVie Inc.'s 3.6%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.

Which stock has higher return on invested capital, AbbVie Inc. or Regeneron Pharmaceuticals, Inc.?▼

ABBV earns 28.7% ROIC versus REGN's 11.8%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

Which dividend is safer, AbbVie Inc.'s or Regeneron Pharmaceuticals, Inc.'s?▼

REGN's dividend earns a safety score of 85/100 (Very Safe), compared to ABBV's 39/100 (Unsafe). REGN has raised its dividend for 0 consecutive years.